Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
XBIO

XBIO - Xenetic Biosciences Inc Stock Price, Fair Value and News

$2.49-0.06 (-2.35%)
Market Closed

52/100

XBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

52/100

XBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.68

Target 3M

$2.66

Target 6M

$2.66

XBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XBIO Price Action

Last 7 days

2.9%

Last 30 days

22.7%

Last 90 days

-24.3%

Trailing 12 Months

-37.9%

XBIO RSI Chart

XBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XBIO Valuation

Market Cap

5.7M

Price/Earnings (Trailing)

-1.81

Price/Sales (Trailing)

2

EV/EBITDA

-0.13

Price/Free Cashflow

-2.1

XBIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.68

Target 3M

$2.66

Target 6M

$2.66

XBIO Fundamentals

XBIO Revenue

Revenue (TTM)

2.9M

Rev. Growth (Yr)

67.19%

Rev. Growth (Qtr)

74.09%

XBIO Earnings

Earnings (TTM)

-3.2M

Earnings Growth (Yr)

-16.78%

Earnings Growth (Qtr)

25.96%

XBIO Profitability

Operating Margin

94.54%

EBT Margin

-586.21%

Return on Equity

-79.78%

Return on Assets

-62.28%

Free Cashflow Yield

-47.64%

XBIO Investor Care

Shares Dilution (1Y)

48.56%

Diluted EPS (TTM)

-2.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20252.6M2.4M2.9M0
20242.4M2.5M2.5M2.5M
20231.9M2.2M2.4M2.5M
20221.4M1.5M1.6M1.7M
2021571.4K746.1K979.4K1.2M
20204.7M3.3M1.9M436.9K
20190006.2M
20174.1M5.3M6.4M7.6M
20160003.0M
20150000
20140000
20130221.9K78.4K692.8K
201200126.7K210.1K
Get all data in R, Python etc through our Historical Stock Data APIs

About Xenetic Biosciences Inc

XBIO
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
 CEO
 WEBSITExeneticbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES4

Xenetic Biosciences Inc Frequently Asked Questions

XBIO is the stock ticker symbol of Xenetic Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Xenetic Biosciences Inc is 5.7 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check XBIO's fair value in chart for subscribers.

The fair value guage provides a quick view whether XBIO is over valued or under valued. Whether Xenetic Biosciences Inc is cheap or expensive depends on the assumptions which impact Xenetic Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XBIO.

As of Wed Jan 28 2026, XBIO's PE ratio (Price to Earnings) is -1.81 and Price to Sales (PS) ratio is 2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XBIO PE ratio will change depending on the future growth rate expectations of investors.